InVivoMab anti-mouse CD8 (Lyt 2.1) BE0118-R050mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMab anti-mouse CD8 (Lyt 2.1)
InVivoMab anti-mouse CD8 (Lyt 2.1)

InVivoMab anti-mouse CD8 (Lyt 2.1)

Be the first to write a review!

Citations:

Supplier Page from
Bio X Cell for
InVivoMab anti-mouse CD8 (Lyt 2.1)

Bio X Cell's InVivoMab anti-mouse CD8 (Lyt 2.1) is a Mouse monoclonal antibody. The InVivoMab anti-mouse CD8 (Lyt 2.1) Antibody was generated using CD8A as the antigen. It reacts with Mouse. This antibody has been shown to work in applications such as: Removal, In Vivo, and Flow Cytometry.

Description

Bio X Cell InVivoMAb anti-mouse CD8 (Lyt 2.1) Monoclonal Antibody has the following reported applications: in vivo CD8+ T cell depletion, Flow cytometry. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-mouse CD8 (Lyt 2.1)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0118-R050mg
Quantity50 mg
Applicationsin vivo CD8+ T cell depletion, Flow cytometry
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
Reactivitymouse
TargetCD8
IsotypeIgG2a, κ
Clone116-13.1 (HB-129)
Hostmouse
NCBI Full Gene NameCD8 subunit alpha
NCBI Gene AliasesLy-2, Ly-35, Ly-B, Lyt-2
ClonalityMonoclonal
ImmunogenCE mouse spleen cells and thymocytes
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaImmunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repressionNature communicationsMarch 20, 2019Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, et al.

(2) MHC-mismatched chimerism is required for induction of transplantation tolerance in autoimmune nonobese diabetic recipientsJournal of immunology (Baltimore, Md. : 1950)August 15, 2014Wang M, Racine J, Zhang M, Wu T, Deng R, Johnston H, Shen C, Siswanto K, Zeng D.

(3) Induction of mixed chimerism depletes pre-existing and de novo-developed autoreactive B cells in autoimmune NOD miceDiabetesJune 1, 2014Racine JJ, Wang M, Zhang M, Zeng D.

(4) Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40BloodNovember 29, 2012Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P.

(5) Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic miceJournal of the American Society of Nephrology : JASNAugust 1, 2003Makhlouf L, Yamada A, Ito T, Abdi R, Ansari MJ, Khuong CQ, Winn HJ, Auchincloss H Jr, Sayegh MH.

(6) Induction of central deletional T cell tolerance by gene therapyJournal of immunology (Baltimore, Md. : 1950)August 15, 2002Kang ES, Iacomini J.

Be the First to Write a Review!